Volume 18, Number 1—January 2012
CME ACTIVITY - Research
Accelerating Control of Pertussis in England and Wales
Helen Campbell
, Gayatri Amirthalingam, Nick Andrews, Norman K. Fry, Robert C. George, Timothy Harrison, and Elizabeth Miller
, Gayatri Amirthalingam, Nick Andrews, Norman K. Fry, Robert C. George, Timothy Harrison, and Elizabeth Miller
Table 6
Effectiveness of pertussis vaccine among pertussis-infected infants 9 weeks to <6 months of age, England, 2002–2009*
| No. doses received before disease onset | No. vaccinated case-patients/total no. (%)† | Average % coverage in comparable population† | % VE (95% CI) |
|---|---|---|---|
| 1 | 174/428 (41) | 64 | 62 (53–69) |
| 2 | 36/91 (40) | 82 | 85 (77–91) |
| 3 | 5/24 (21) | 84 | 95 (86–99) |
*Data are for culture-, PCR-, and serology-confirmed cases with onset during 2002–2009. Case-patients received 1 of the following 3 vaccine regimens: 1) DTwP (diphtheria/tetanus/whole-cell pertussis) or DTaP3 (DT/3-component acellular pertussis vaccine) at 2, 3, and 4 mo of age; 2) DTwP at 2, 3, and 4 mo of age; or 3) DTaP5 at 2, 3, and 4 mo of age. VE, vaccine effectiveness.
†Coverage for 1, 2, and 3 doses was calculated by using the number of doses received or 0 doses. Note that case-patients with 0 doses may be counted in >1 group.
Page created: December 23, 2011
Page updated: December 23, 2011
Page reviewed: December 23, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.